ADCT SEC Filings - Adc Therapeutics Sa 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Adc Therapeutics SA's (ADCT) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms. It details how the company, an oncology firm specializing in antibody drug conjugates, uses these filings to report financial results, clinical trial updates for its drug ZYNLONTA, corporate presentations, and capital-raising activities. The platform enhances these documents with AI-powered summaries to help investors quickly understand key information.
Has ADC Therapeutics (ADCT) outpaced other medical stocks this year?
This article from MSN focuses on ADC Therapeutics (ADCT) and its performance compared to other medical stocks. It aims to determine if ADCT has shown superior growth or returns within the medical sector this year.
Has ADC Therapeutics (ADCT) outpaced other medical stocks this year?
The article analyzes if ADC Therapeutics (ADCT) has outperformed other medical stocks this year. It suggests that comparing various medical stocks can help investors determine if ADCT is a strong performer in the sector. The content implies that the article itself would delve into performance metrics to answer this question.
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
ADC Therapeutics SA (NYSE:ADCT) has received a "Moderate Buy" consensus rating from analysts, with five buy ratings and one sell rating. The average 12-month target price is $7.50, significantly higher than its current trading price of around $4.00. The company, which specializes in antibody-drug conjugates, recently reported earnings per share of ($0.30), beating estimates, though revenue of $16.4 million slightly missed.
ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is Lacking
ADC Therapeutics SA (NYSE:ADCT) currently has a price-to-sales (P/S) ratio of 6.7x, which appears low compared to the Biotech industry average. However, this low P/S ratio is attributed to the company's lagging revenue growth, with a 52% decline over the past three years. Analysts forecast a 50% annual revenue growth for ADC Therapeutics over the next three years, significantly less than the industry's predicted 137% growth, explaining the stock's reduced valuation.
ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is Lacking
ADC Therapeutics SA (NYSE:ADCT) exhibits a lower-than-industry price-to-sales (P/S) ratio of 6.7x, which may suggest it's a good buy, yet this is likely due to its sluggish revenue growth. While the company's revenue increased by 6.4% in the last year, it experienced a significant 52% drop over the past three years. Analysts project a 50% annual growth for ADC Therapeutics in the next three years, which is still considerably lower than the industry's anticipated 137% growth, explaining the company's lower P/S ratio.
Update On ADCs: Sales, Deals, Targets And Approvals
This article provides an update on Antibody-Drug Conjugates (ADCs), covering areas such as sales, deals, targets, and approvals. It is authored by David Wild and published on February 5, 2026.
ADC Therapeutics Grants Stock Options to New Employees
ADC Therapeutics granted stock options for 308,000 common shares to seven new employees on February 2, 2026, as an inducement for employment, aiming to retain and motivate them. The options will vest over four years, with 25% on the first anniversary and monthly thereafter, and comply with NYSE Rule 303A.08. The company is known for developing antibody-drug conjugates (ADCs), including its FDA-approved product ZYNLONTA.
ADC Therapeutics (ADCT) upgraded to buy: Here's why
This article announces that ADC Therapeutics (ADCT) has received an analyst upgrade to a "Buy" rating. It suggests that the stock is now considered a more favorable investment by the analysis community. The article implies further details within about the reasoning behind this upgrade.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics SA announced grants of options to purchase 308,000 common shares to seven new employees on February 2, 2026. These grants serve as a material inducement for their employment, aiming to motivate high performance and significant contributions to the company's success. The options will vest over four years, contingent on continued employment.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics SA (NYSE: ADCT) announced grants of options to purchase 308,000 common shares to seven new employees on February 2, 2026. These grants serve as a material inducement for their employment, approved by the Compensation Committee under the Company's Inducement Plan. The shares will vest over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter, contingent on continued employment.
ADC Therapeutics Faces Securities Fraud Investigation, Stock Drops 14.13%
ADC Therapeutics is under investigation by Pomerantz LLP for potential securities fraud following a 14.13% stock drop. This decline occurred after the release of LOTIS-7 trial data on December 3, 2025, which showed a 36.7% rate of cytokine release syndrome among patients, raising investor concerns despite the company's positive spin. The investigation and adverse clinical data could lead to significant financial liabilities and impact investor confidence in ADC Therapeutics' future prospects.
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 47.2%
Short interest in ADC Therapeutics SA (NYSE:ADCT) significantly decreased by 47.2% in December, with the total shorted shares falling to 3,573,570. The company's stock recently traded down 5.0% to $3.53, though it has a "Moderate Buy" consensus rating with a $7.50 target price from analysts. Institutional investors own 41.1% of the shares, with several funds increasing their positions in recent quarters.
ADCT: Zynlonta's pivotal trials aim to transform its market reach and drive major growth from 2027
ADC Therapeutics' drug Zynlonta is undergoing pivotal trials (LOTIS-5 and LOTIS-7) to expand its use beyond third-line DLBCL into earlier treatment lines and indolent lymphomas. These trials are anticipated to significantly boost revenue growth for ADCT from 2027, driven by Zynlonta's strong efficacy, rapid response, and favorable safety profile. The information is based on an audio transcript from the 44th Annual J.P. Morgan Healthcare Conference.
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
ADC Therapeutics (ADCT) is currently outperforming the Medical sector year-to-date, with an 8.2% gain compared to the sector's 7.5% average. The company holds a strong Zacks Rank #2 (Buy) due to a significant 36.3% increase in its full-year earnings consensus estimate over the last 90 days. However, ADCT is slightly underperforming its specific industry, Medical - Biomedical and Genetics, which has gained 18.9% this year.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating ADC Therapeutics SA (NYSE: ADCT) on behalf of investors for potential securities fraud. This investigation follows a December 3, 2025, press release regarding updated data from the LOTIS-7 clinical trial, which, despite being framed positively, reported adverse events and cytokine release syndrome in a significant percentage of patients. Following this news, ADC's stock price dropped by 14.13%.
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
ADC Therapeutics SA (NYSE:ADCT) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month price target of $7.50. Five analysts issued buy ratings and one a sell rating. Institutional investors and hedge funds own approximately 41.1% of the stock, with significant recent increases in positions by firms like JPMorgan Chase & Co. and TCG Crossover Management LLC.
ADC Therapeutics posts preliminary 2025 revenue of about $73M
ADC Therapeutics announced preliminary revenue of approximately $73 million for 2025, driven by strong sales of ZYNLONTA. The company also reported closing a $130 million financing round and expects net product sales of ZYNLONTA to be between $80 million and $85 million in 2026. These updates precede a webcast presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Cancer drug combo shows nearly 90% response rate in lymphoma trial
ADC Therapeutics (ADCT) reported preliminary 2025 ZYNLONTA net product revenue of approximately $73 million and ended the year with $261 million in cash, providing a runway until at least 2028. The company also announced updated data from its LOTIS-7 trial, showing an 89.8% overall response rate and 77.6% complete response rate in lymphoma patients, with full enrollment expected in H1 2026. Topline results for the LOTIS-5 Phase 3 trial are anticipated in Q2 2026, which could lead to regulatory approvals and compendia inclusion for ZYNLONTA.
What ADC Therapeutics will share at J.P. Morgan's health conference
ADC Therapeutics (NYSE: ADCT) announced that CEO Ameet Mallik will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 10:30 a.m. PT. A live webcast will be available for investors on the company’s website, with a replay accessible for approximately 30 days. The presentation offers stakeholders an opportunity to gain insights into the company's strategy, clinical programs, and financing position.
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
ADC Therapeutics announced preliminary unaudited Q4 and full-year 2025 revenue and cash estimates, with ZYNLONTA net product revenue reaching approximately $73 million for the full year. The company reported cash and cash equivalents of $261 million as of December 31, 2025, providing a cash runway extended at least until 2028. Key upcoming catalysts include the full enrollment of LOTIS-7 in 1H 2026 and topline data from the LOTIS-5 Phase 3 trial in 2Q 2026, aiming for potential compendia inclusions and regulatory approvals thereafter.
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
ADC Therapeutics announced that its CEO, Ameet Mallik, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 10:30 a.m. PT. A live webcast of the presentation will be available on the company's website. ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs), known for its product ZYNLONTA.
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
ADC Therapeutics announced preliminary unaudited fourth quarter and full-year 2025 revenue estimates and cash reserves, projecting a cash runway through at least 2028. The company also provided updates on its ZYNLONTA clinical program, including anticipated topline data for LOTIS-5 in Q2 2026 and complete enrollment for LOTIS-7 in the first half of 2026. These developments are expected to accelerate net product revenue growth starting in 2027, with potential regulatory approvals and compendia inclusions following positive trial results.
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
ADC Therapeutics announced preliminary unaudited fourth-quarter and full-year 2025 revenue and cash estimates, with ZYNLONTA net product revenue expected to be approximately $73 million for the full year. The company anticipates a cash runway extending at least to 2028, supported by its cash and cash equivalents of approximately $261 million as of December 31, 2025. Key upcoming catalysts include complete enrollment for LOTIS-7 in the first half of 2026 and topline data from the LOTIS-5 Phase 3 trial in the second quarter of 2026, with potential regulatory approvals and compendia inclusions expected in subsequent periods.
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
ADC Therapeutics SA (NYSE: ADCT) announced its CEO, Ameet Mallik, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be webcast live and will introduce investors to the company's progress as a commercial-stage global leader in antibody drug conjugates, featuring its product ZYNLONTA. The company continues to advance its research and development pipeline.
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
ADC Therapeutics (NYSE: ADCT) announced its CEO, Ameet Mallik, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, in San Francisco. A live webcast of the presentation will be available on the company's investor relations website. ADC Therapeutics is a commercial-stage global leader in antibody-drug conjugates, known for its treatment ZYNLONTA.
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
ADC Therapeutics announced preliminary unaudited Q4 and full year 2025 net product revenue of approximately $22M and $73M respectively, with cash and cash equivalents of $261M as of December 31, 2025, extending their cash runway at least to 2028. The company anticipates key clinical catalysts in 2026, including complete enrollment for LOTIS-7 and topline data for LOTIS-5, with potential regulatory approvals and compendia inclusions expected to follow, driving revenue growth beginning in 2027.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (NYSE: ADCT) concerning potential securities fraud or unlawful business practices. This investigation follows a December 3, 2025, press release where ADC reported adverse events and cytokine release syndrome in patients during a clinical trial, leading to a 14.13% drop in the company's stock price.
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics SA announced a grant of options to purchase 6,000 common shares to a new employee on January 2, 2026. This grant serves as a material inducement for employment and was approved by the Compensation Committee under the Company's Inducement Plan. The options will vest over four years, subject to continued employment, in reliance on the NYSE's employment inducement exemption.
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics SA (NYSE: ADCT) has announced a new employee inducement grant of options to purchase 6,000 common shares. This grant was approved by the Compensation Committee of the Company's Board of Directors under the Inducement Plan, aiming to motivate the new employee. The options will vest over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter, subject to continued employment.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential claims against ADC Therapeutics SA on behalf of its investors. This investigation follows a significant 14.13% drop in ADC Therapeutics' stock price on December 3, 2025, after a press release detailed adverse events in a clinical trial, including cytokine release syndrome in a substantial percentage of patients. Investors are advised to contact Danielle Peyton at Pomerantz LLP for more information regarding this securities fraud investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (NYSE: ADCT) on behalf of investors. This investigation follows a December 3, 2025 press release where ADC disclosed adverse events and cytokine release syndrome in a clinical trial for ZYNLONTA®, leading to a 14.13% drop in the company's stock price. The firm is inviting affected investors to contact them regarding a possible class action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (NYSE:ADCT) on behalf of its investors. This investigation follows a December 3, 2025 announcement regarding updated data from the LOTIS-7 clinical trial, which, despite being described positively, reported adverse events and a significant incidence of cytokine release syndrome, leading to a 14.13% stock price drop. Investors are encouraged to contact the firm for more information.
Corient Private Wealth LLC Makes New Investment in ADC Therapeutics SA $ADCT
Corient Private Wealth LLC has made a new investment in ADC Therapeutics SA, purchasing 357,880 shares valued at approximately $959,000. Institutional ownership of ADCT stock is currently at 41.10%. Analysts have given the company a "Moderate Buy" consensus rating with an average price target of $7.50.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (NYSE: ADCT) following a December 3, 2025 announcement regarding data from its LOTIS-7 Phase 1b clinical trial. Despite positive framing, the press release revealed adverse events and cytokine release syndrome in a significant percentage of patients, causing ADC's stock price to fall by 14.13%. Investors who suffered losses are encouraged to contact the law firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (NYSE: ADCT) following a December 3, 2025, press release. Despite positive framing, the release detailed adverse events, including treatment-related issues in two patients and cytokine release syndrome in 36.7% of patients in a clinical trial. This news led to a 14.13% drop in ADC's stock price.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (NYSE: ADCT) following a December 3, 2025 announcement. The announcement concerned updated data from the LOTIS-7 Phase 1b clinical trial, which, despite being described positively, indicated adverse events and a high rate of cytokine release syndrome among patients. Following this news, ADC Therapeutics' stock price fell by 14.13%.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating claims against ADC Therapeutics SA (NYSE:ADCT) on behalf of investors, following a significant drop in stock price. This comes after the company released updated data from its LOTIS-7 Phase 1b clinical trial, which, despite being described positively, reported adverse events and cytokine release syndrome in a notable percentage of patients. Investors are encouraged to contact the firm if they have suffered losses.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (NYSE:ADCT) on behalf of investors. This investigation follows a 14.13% stock price drop on December 3, 2025, after the company announced updated data from a clinical trial, which, despite being described positively, reported adverse events and a high percentage of cytokine release syndrome among patients. Investors are encouraged to contact the firm for more information regarding a potential class action.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (NYSE:ADCT) on behalf of investors. This investigation follows a 14.13% drop in ADC's stock price after the company released updated data from its LOTIS-7 clinical trial, which, despite being described positively, reported adverse events including a 36.7% incidence of cytokine release syndrome among patients. Investors who believe they may have been affected are advised to contact the law firm.
ADC Therapeutics SA (NYSE:ADCT) Given Average Rating of "Moderate Buy" by Brokerages
ADC Therapeutics SA (NYSE:ADCT) has received a "Moderate Buy" rating from brokerages, with five out of six analysts issuing a buy rating and one a sell rating. The average 12-month price target is set at $7.50. Institutional ownership has increased, with approximately 41.10% of shares now held by institutional investors and hedge funds, reflecting increased confidence in the company.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (NYSE:ADCT) on behalf of investors. This investigation follows a December 3, 2025 press release regarding updated data from the LOTIS-7 clinical trial, which, despite being described positively, reported adverse events and cytokine release syndrome in a significant percentage of patients. Following this news, ADC Therapeutics' stock price dropped by 14.13%.
RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development
RBC Capital has reiterated an Outperform rating for ADC Therapeutics S.A. (ADCT) with a $5.00 price target after reviewing new Phase Ib data from the LOTIS-7 trial. The trial for ZYNLONTA showed promising results in treating relapsed or refractory diffuse large B-cell lymphoma, demonstrating a high overall response rate and complete response rate. This positive outlook positions ZYNLONTA-based combinations as potential improvements for 2L+ DLBCL patients.
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
ADC Therapeutics SA (ADCT) has significantly outperformed its Medical sector peers and its specific "Medical - Biomedical and Genetics" industry year-to-date, returning 99.5% compared to the sector's 6.2% average gain and the industry's 18.4% gain. The company holds a strong Zacks Rank #2 (Buy) due to a 15% increase in its full-year earnings consensus estimate within the last quarter. Investors are encouraged to monitor ADCT and Catalyst Pharmaceutical (CPRX) given their solid performance.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential claims on behalf of investors of ADC Therapeutics SA (NYSE:ADCT). This investigation follows a December 3, 2025, press release where ADC Therapeutics announced updated data from its LOTIS-7 Phase 1b trial, which led to a significant 14.13% drop in the company's stock price due to reported adverse events. The law firm is examining whether the company and its leadership engaged in securities fraud or unlawful business practices.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (NYSE:ADCT) stemming from a December 3, 2025 press release. The company announced updated positive data from a clinical trial but also reported adverse events and cytokine release syndrome in a significant percentage of patients. Following this news, ADC Therapeutics' stock price fell by 14.13%.
ADC Therapeutics (NYSE:ADCT) Sees Large Volume Increase - Still a Buy?
ADC Therapeutics (NYSE:ADCT) experienced a significant 144% increase in trading volume, with 1,839,645 shares traded, while its stock price remained relatively flat at $4.22. Despite the company remaining unprofitable with a projected full-year EPS of -$1.69, analysts have a "Moderate Buy" consensus rating and an average price target of $7.50, suggesting a notable upside. The company recently reported Q3 EPS of -$0.30, beating estimates by $0.10, though revenue slightly missed expectations.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (NYSE: ADCT) following a December 3, 2025 press release. Despite positive framing, the release detailed adverse events, including treatment-related issues and cytokine release syndrome, from their LOTIS-7 clinical trial. This news led to a 14.13% drop in ADC Therapeutics' stock price, prompting the law firm's investigation into unlawful business practices on behalf of investors.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (ADCT) on behalf of investors. The investigation follows a decline in ADC's stock price after the company released updated data from its LOTIS-7 clinical trial, which revealed adverse events and cytokine release syndrome in patients. Investors are encouraged to contact Pomerantz LLP for more information.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics SA (NYSE:ADCT) on behalf of investors. This investigation follows a press release from ADC Therapeutics regarding adverse events and cytokine release syndrome observed in a clinical trial, which caused the company's stock price to fall. The law firm is inviting affected investors to contact them regarding a potential class action lawsuit.
